Who is sponsoring NCT04543851?

NCT04543851 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT04543851?

Interventions in NCT04543851: CARA - carbon fibre adjustable re-usable accessory for breast positioning.

What condition does NCT04543851 study?

NCT04543851 studies Breast Cancer, Side Effect.

Is NCT04543851 still recruiting?

NCT04543851 is currently completed. Last updated 10 September 2020.

Last reviewed 2020-09-10 · How we verify

NCT04543851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CARA Treatment Pilot Study for Breast Positioning

Completed NA Last updated 10 September 2020

What this trial tests

NA trial testing CARA - carbon fibre adjustable re-usable accessory for breast positioning in Breast Cancer in 20 participants. Completed in 18 November 2019.

Timeline

8 October 2018

Primary endpoint
4 November 2019

18 November 2019

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 October 2018
Primary completion	4 November 2019
Estimated completion	18 November 2019
Sites	1 location across Canada

Drugs / interventions tested

CARA - carbon fibre adjustable re-usable accessory for breast positioning

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Side Effect — all drugs for Side Effect →

Sponsor

British Columbia Cancer Agency

Who can join

19 and older, any sex, with Breast Cancer or Side Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CARA is a novel Carbon-fibre Adjustable and Re-usable Accessory for supine breast positioning during radiation therapy. CARA was developed at BC Cancer. In this study, twenty patients will be planned and treated with CARA positioning to establish safety and workflow measures of this novel device. The device is designed to remove the infra-mammary skin fold and lateral breast droop which can lead to unwanted dose to normal tissue.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Reduction in Doses to Organs at Risk and Normal Tissue During Breast Radiation Therapy With a Carbon-Fiber Adjustable Reusable Accessory.
Duzenli C, Koulis T, Menna T, Carpentier E, et al · · 2021 · cited 5× · PMID 34303034 · DOI 10.1016/j.prro.2021.06.012
Toward a Skin Dose-Area Metric Predictive of Moist Desquamation Using In Vivo Skin Dosimetry and Skin Assessments.
Malhotra A, Carpentier EE, Grahame S, Chan EK, et al · · 2024 · cited 3× · PMID 38260224 · DOI 10.1016/j.adro.2023.101318
Recommendations for using analytical anisotropic algorithm and AcurosXB for epidermal dose calculations in breast radiotherapy from an in vivo Gafchromic film study.
Malhotra A, Carpentier EE, Duzenli C. · · 2024 · cited 2× · PMID 38812120 · DOI 10.1002/acm2.14416
Spatial dose-distribution-based risk mapping to predict moist desquamation in breast radiotherapy.
Malhotra A, Chan EK, Nichol A, Duzenli C. · · 2025 · PMID 40373801 · DOI 10.1088/1361-6560/add985

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04543851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 10 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04543851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing